These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
660 related articles for article (PubMed ID: 21036486)
1. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486 [TBL] [Abstract][Full Text] [Related]
2. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999 [TBL] [Abstract][Full Text] [Related]
3. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Ko EC; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944 [TBL] [Abstract][Full Text] [Related]
4. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039 [TBL] [Abstract][Full Text] [Related]
5. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182 [TBL] [Abstract][Full Text] [Related]
7. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir. Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102 [TBL] [Abstract][Full Text] [Related]
8. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
9. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer. Lilleby W; Tafjord G; Raabe NK Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456 [TBL] [Abstract][Full Text] [Related]
10. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
11. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Vicini FA; Kestin LL; Martinez AA Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815 [TBL] [Abstract][Full Text] [Related]
12. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report. Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
15. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851 [TBL] [Abstract][Full Text] [Related]
16. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435 [TBL] [Abstract][Full Text] [Related]
17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy. Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487 [TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287 [TBL] [Abstract][Full Text] [Related]
20. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]